PL2371382T3 - Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń - Google Patents

Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń

Info

Publication number
PL2371382T3
PL2371382T3 PL11164849T PL11164849T PL2371382T3 PL 2371382 T3 PL2371382 T3 PL 2371382T3 PL 11164849 T PL11164849 T PL 11164849T PL 11164849 T PL11164849 T PL 11164849T PL 2371382 T3 PL2371382 T3 PL 2371382T3
Authority
PL
Poland
Prior art keywords
pigs
immunogenic composition
clinical symptoms
pcv2 immunogenic
lessening
Prior art date
Application number
PL11164849T
Other languages
English (en)
Inventor
Michael B Roof
Marc Allan Eichmeyer
Greg Nitzel
Phillip Wayne Hayes
Merrill Lynn Schaeffer
Original Assignee
Boehringer Ingelheim Vetmedica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38371964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2371382(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc
Publication of PL2371382T3 publication Critical patent/PL2371382T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL11164849T 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń PL2371382T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75501605P 2005-12-29 2005-12-29
US82980906P 2006-10-17 2006-10-17
EP06850366.3A EP1976558B1 (en) 2005-12-29 2006-12-28 Pcv2 immunogenic composition for lessening clinical symptoms in pigs
EP11164849.9A EP2371382B1 (en) 2005-12-29 2006-12-28 Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs

Publications (1)

Publication Number Publication Date
PL2371382T3 true PL2371382T3 (pl) 2016-08-31

Family

ID=38371964

Family Applications (5)

Application Number Title Priority Date Filing Date
PL11164854T PL2371385T3 (pl) 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164850T PL2371383T3 (pl) 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164849T PL2371382T3 (pl) 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń
PL16185663T PL3127551T3 (pl) 2005-12-29 2006-12-28 Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń
PL20184598.9T PL3766518T3 (pl) 2005-12-29 2006-12-28 Kompozycja immunogenna zawierająca pcv2 do zmniejszania objawów klinicznych u świń

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL11164854T PL2371385T3 (pl) 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164850T PL2371383T3 (pl) 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL16185663T PL3127551T3 (pl) 2005-12-29 2006-12-28 Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń
PL20184598.9T PL3766518T3 (pl) 2005-12-29 2006-12-28 Kompozycja immunogenna zawierająca pcv2 do zmniejszania objawów klinicznych u świń

Country Status (19)

Country Link
US (12) US20080181910A1 (pl)
EP (11) EP2371386A1 (pl)
JP (2) JP5739602B2 (pl)
KR (2) KR20140019479A (pl)
CN (4) CN101426522B (pl)
AR (1) AR058871A1 (pl)
AU (1) AU2006338182B2 (pl)
BR (1) BRPI0620823B1 (pl)
CA (1) CA2635430A1 (pl)
DK (6) DK2371382T3 (pl)
ES (6) ES2824113T3 (pl)
FI (1) FI3766518T3 (pl)
HU (4) HUE051784T2 (pl)
MX (4) MX338626B (pl)
PL (5) PL2371385T3 (pl)
PT (4) PT2371383E (pl)
SG (1) SG170792A1 (pl)
TW (1) TW200800256A (pl)
WO (1) WO2007094893A2 (pl)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
DK2275132T3 (da) 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
CA2635430A1 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) * 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2094872T (pt) * 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2710247C (en) * 2007-12-21 2014-02-18 Wyeth Llc Methods and compositions for immunizing pigs against porcine circovirus
CN101932336B (zh) * 2007-12-31 2014-07-09 贝林格尔.英格海姆维特梅迪卡有限公司 有外来氨基酸插入的pcv2 orf2病毒样颗粒
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
EP2254595A4 (en) * 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES
TWI449533B (zh) 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
TWI627281B (zh) * 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
US9932372B2 (en) 2010-07-08 2018-04-03 United Biomedical, Inc. Designer peptide-based PCV2 vaccine
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
CA2925281C (en) 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
ES2778425T3 (es) 2013-10-02 2020-08-10 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína ORF2 del PCV2 y partículas similares a virus compuestas por esta
WO2015082457A1 (en) 2013-12-03 2015-06-11 Intervet International B.V. Vaccine against lawsonia intracellularis and porcine circovirus 2
PL3076996T3 (pl) 2013-12-03 2020-05-18 Intervet International B.V. Szczepionka przeciwko cirkowirusowi świń typu 2
RU2744193C2 (ru) * 2015-10-16 2021-03-03 Канзас Стейт Юниверсити Рисерч Фаундейшн Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
WO2017113050A1 (zh) * 2015-12-28 2017-07-06 财团法人农业科技研究院 猪圆环病毒2型的外鞘蛋白质的制备方法及含该外鞘蛋白质的医药组合物
RU2018137036A (ru) 2016-03-23 2020-04-23 Интервет Интернэшнл Б.В. Комбинированная вакцина против инфекции вирусами pcv2 и prrs, содержащая альбумин
BR112018069219A2 (pt) * 2016-03-23 2019-01-22 Intervet Int Bv uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
BR112018069100A2 (pt) 2016-03-23 2019-01-29 Intervet International B.V. uma vacina combinada contra a infecção por vírus pcv2 e mycoplasma hyopneumoniae
US11622872B2 (en) 2016-05-16 2023-04-11 Elixir Medical Corporation Uncaging stent
ES2873887T3 (es) 2016-05-16 2021-11-04 Elixir Medical Corp Liberación de stent
UA130511C2 (uk) 2016-11-03 2026-03-11 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання
CA3058281A1 (en) 2017-04-13 2018-10-18 Intervet International B.V. Vaccines containing swine pathogens for associated non-mixed use
US12599490B2 (en) 2017-05-25 2026-04-14 Elixir Medical Corporation Uncaging stent
CN109010818B (zh) * 2017-06-09 2021-11-09 普莱柯生物工程股份有限公司 一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
EP3661548B1 (en) 2017-08-03 2024-06-26 Intervet International B.V. A vaccine comprising a pcv2 orf2 protein of genotype 2b
CN112773583B (zh) 2017-08-11 2024-01-09 万能医药公司 撑开支架
BR112020002804A2 (pt) 2017-08-24 2020-07-28 Novo Nordisk A/S composição farmacêutica líquida, e, kit
CN119488586A (zh) 2018-03-26 2025-02-21 勃林格殷格翰动物保健美国有限公司 制备免疫原性组合物的方法
CN114222579A (zh) 2019-04-04 2022-03-22 勃林格殷格翰动物保健美国有限公司 猪圆环病毒3型（pcv3）疫苗及其生产和用途
CN114364398B (zh) 2019-09-12 2025-08-22 英特维特国际股份有限公司 用于皮内施用的联合疫苗
IL294521A (en) 2020-02-18 2022-09-01 Novo Nordisk As glp-1 compounds and their uses
FR3107454B1 (fr) 2020-02-20 2023-02-10 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Adjuvant de vaccin comprenant un microlatex inverse
MX2022013080A (es) 2020-04-20 2022-11-10 Intervet Int Bv Una combinacion de vacunas para el tratamiento profilactico de un cerdo.
US20230241198A1 (en) 2020-07-24 2023-08-03 Boehringer Ingelheim Animal Health USA Inc. Combination porcine vaccine
US20240009303A1 (en) 2020-10-29 2024-01-11 Intervet Inc. Combination vaccine for protecting swine against various disorders
WO2026099754A1 (en) * 2024-11-06 2026-05-15 Boehringer Ingelheim Vetmedica Gmbh Method for reducing virus shedding, tissue colonization, and lymphoid depletion caused by or associated with pcv2 infection

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US755016A (en) 1903-06-08 1904-03-22 Charles Herschel Koyl Coal-separating apparatus.
US829809A (en) 1906-04-10 1906-08-28 Arthur H Swan Peel-blade tip.
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US3479705A (en) 1966-12-15 1969-11-25 Miami Brick & Stone Inc Of Mia Molding apparatus
NL7903764A (nl) 1979-05-14 1980-11-18 Shell Int Research Werkwijze ter bereiding van calcium-houdend lood, daarmee verkregen lood en daaruit verkregen accuplaten of -roosters.
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ES2052685T3 (es) 1987-03-17 1994-07-16 Akzo Nv Metodo para producir un adyuvante libre.
US5069901A (en) 1988-02-03 1991-12-03 Jones Elaine V Preparation of a recombinant subunit vaccine against pseudorabies infection
DE69027112T2 (de) 1989-01-23 1997-01-09 Auspharm International Ltd 4Th Impfstoffzusammensetzung
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) * 1990-01-16 1993-04-13 University Of Tennessee Transmissible gastroenteritis virus genes
AU657907B2 (en) 1990-05-29 1995-03-30 Wyeth Holdings Corporation Mycoplasma hyopneumoniae vaccine
JP3046332B2 (ja) * 1990-08-02 2000-05-29 協和醗酵工業株式会社 発酵法によるアミノ酸の製造法
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
NL9301272A (nl) 1993-07-20 1995-02-16 Aesculaap Bv Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
GB9023111D0 (en) * 1990-10-24 1990-12-05 Wellcome Found Expression system
WO1992007934A1 (en) * 1990-11-01 1992-05-14 Iowa State University Research Foundation, Inc. Bacterial attenuation method and vaccine
US6042830A (en) 1992-08-05 2000-03-28 Boehringer Ingelheim Vetmedica, Inc. Viral agent associated with mystery swine disease
MX9204885A (es) 1991-08-26 1994-05-31 Boehringer Animal Health Inc Composicion de vacuna que comprende virus del sindrome de infertilidad y respiratorio de los cerdos.
US5580557A (en) 1991-10-09 1996-12-03 Iowa State University Research Foundation, Inc. Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en) 1992-02-27 1994-08-16 Ambico, Inc. Thimerosal inactivated mycoplasma hyopneumoniae vaccine
CN1070078C (zh) * 1993-11-24 2001-08-29 中国农科院兰州兽医研究所 口蹄疫疫苗的生产工艺
EP1820512B1 (en) 1994-05-10 2013-07-03 Boehringer Ingelheim Vetmedica, Inc. Improved modified live brsv vaccine
US5885823A (en) 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO1998006855A1 (en) 1996-08-16 1998-02-19 The Texas A & M University System Compositions and methods for delivery of nucleic acids to hepatocytes
ES2157522T3 (es) 1996-10-09 2001-08-16 Akzo Nobel Nv Cepas de vacunas europeas del virus del sindrome respiratorio reproductor porcino (prrsv).
AU2002302120B2 (en) * 1997-10-03 2006-01-19 Merial Porcine circoviruses, vaccines and diagnostic reagents
US7192594B2 (en) 1997-10-03 2007-03-20 Merial Limited Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr) 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
US7211379B2 (en) 1997-10-03 2007-05-01 Merial Sas Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US20040062775A1 (en) 1997-12-05 2004-04-01 Agence Francaise De Securite Sanitaire Des Aliments Circovirus sequences associated with piglet weight loss disease (PWD)
JP3795751B2 (ja) 1997-12-11 2006-07-12 ユニバーシティ オブ サスカッチェワン ブタからの離乳後多全身系消耗症候群ウイルス
WO1999045956A1 (en) 1998-03-13 1999-09-16 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
DE19836659A1 (de) 1998-08-13 2000-02-17 Hoechst Schering Agrevo Gmbh Herbizide Mittel für tolerante oder resistente Baumwollkulturen
EP1050584B1 (en) 1998-11-19 2006-10-18 Azwell Inc. Recombinant lysophosphatidic acid phosphatase
FR2789695B1 (fr) * 1999-02-11 2003-03-07 Merial Sas Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
GB9921146D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001017556A1 (fr) 1999-09-07 2001-03-15 Shionogi & Co., Ltd. Préparations vaccinales administrables par les muqueuses
US6656478B1 (en) 1999-11-12 2003-12-02 Samuel D. Charles Cross-protective salmonella vaccines
DE60038048T2 (de) 1999-12-21 2009-07-09 Merial Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
US6808900B2 (en) * 2000-06-15 2004-10-26 Manitoba, University Of Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
WO2001096377A2 (en) 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
MY129765A (en) 2000-12-19 2007-04-30 Wyeth Corp Improved mycoplasma hyopneumoniae bacterin vaccine
US7018638B2 (en) * 2000-12-19 2006-03-28 Wyeth Mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja) 2001-02-23 2002-09-03 Nippon Biologicals Inc マレック病ワクチンおよびその製造方法
MY146518A (en) * 2001-03-27 2012-08-15 Univ Saskatchewan Methods to culture circovirus.
US20030096377A1 (en) * 2001-06-28 2003-05-22 Virginia Tech Intellectual Properties, Inc. Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
JP2005515162A (ja) 2001-07-02 2005-05-26 ファイザー・プロダクツ・インク マイコプラズマ・ハイオニューモニエ（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）を用いた単回ワクチン接種
US7361352B2 (en) 2001-08-15 2008-04-22 Acambis, Inc. Influenza immunogen and vaccine
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7279166B2 (en) 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) 2002-01-22 2005-01-11 Protatek International, Inc. Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
WO2003077860A2 (en) 2002-03-13 2003-09-25 Biophysica, Inc. BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
US20030215455A1 (en) * 2002-05-14 2003-11-20 Bailey Reynolds Vaccine stabilizer and method of use
US7194472B2 (en) * 2002-07-05 2007-03-20 Sun Microsystems Inc. Extending role scope in a directory server system
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
US7223207B1 (en) 2002-09-13 2007-05-29 Simon Basyuk Exercise and massage device
AU2002951692A0 (en) 2002-09-23 2002-10-17 Vital Biotech (Hong Kong) Limited Improvements in or relating to vaccines
EP1599164B1 (en) 2003-02-03 2015-04-08 Cerebus Biologicals, Inc. Methods for treating, preventing and detecting helicobacter infection
US7563449B2 (en) 2003-04-21 2009-07-21 Pfizer Inc, Methods for reducing cattle reproductive diseases
CN1458167A (zh) 2003-06-02 2003-11-26 中国农业科学院哈尔滨兽医研究所 截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) 2003-06-09 2008-02-26 Animal Technology Institute Taiwan Fusion antigen used as vaccine
NO321276B1 (no) 2003-07-07 2006-04-18 Elkem Materials Fremgangsmate for fremstilling av triklorsilan og silisium for bruk ved fremstilling av triklorsilan
PL1651265T3 (pl) 2003-07-24 2008-10-31 Merial Ltd Formulacje szczepionek zawierających emulsję olej w wodzie
CA2533559C (en) * 2003-07-25 2013-07-02 Boehringer Ingelheim Vetmedica, Inc. Lawsonia intracellularis of european origin and vaccines, diagnostic agents and methods of use thereof
FR2861731B1 (fr) * 2003-10-30 2006-02-24 Centre Nat Rech Scient Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
CN1942204A (zh) 2004-04-26 2007-04-04 株式会社中央疫苗研究所 用于猪呼吸病的灭活混合疫苗及其制备方法
CN1579553A (zh) * 2004-05-18 2005-02-16 浙江大学 Ii型猪圆环病毒核酸疫苗的制备方法及其应用
KR100478845B1 (ko) 2004-06-22 2005-03-24 채찬희 돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물
KR20070052273A (ko) 2004-06-30 2007-05-21 아이디 바이오메디컬 코포레이션 오브 퀘벡 코로나바이러스 감염의 치료를 위한 백신 조성물
US7258075B1 (en) * 2004-08-13 2007-08-21 World Factory, Inc. Collapsible bird feeder
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) * 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CA2587321A1 (en) 2005-01-13 2006-07-20 Boehringer Ingelheim Vetmedica Gmbh Improved prrs vaccines
US7300785B2 (en) 2005-02-03 2007-11-27 Universiteit Ghent Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en) * 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
MX2007012786A (es) 2005-04-13 2008-01-11 Merial Ltd Ensayo para produccion de circovirus porcino.
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
CN101277717A (zh) * 2005-09-09 2008-10-01 英特威国际有限公司 Pcv-2疫苗
CA2635430A1 (en) * 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
DK2275132T3 (da) 2005-12-29 2021-05-17 Boehringer Ingelheim Animal Health Usa Inc Multivalente pcv2-immunogeniske sammensætninger og fremgangsmåder til at fremstille dem
WO2007094983A2 (en) 2006-02-03 2007-08-23 Tanox, Inc. Methods and compositions for the inhibition of hiv infection of t cells
WO2008064299A2 (en) 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PT2094872T (pt) 2006-12-15 2017-04-27 Boehringer Ingelheim Vetmedica Inc Tratamento de porcos seropositivos para o anticorpo anti-pcv2 com antigénio de pcv2
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en) 2007-06-22 2007-08-01 Univ Ghent Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko) 2008-01-23 2010-10-21 베링거잉겔하임베트메디카인코퍼레이티드 Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
EP2254595A4 (en) 2008-02-15 2012-12-05 Boehringer Ingelheim Vetmed METHODS AND COMPOSITIONS FOR REDUCING THE IMPACT OF ENTERIC DISEASES
US8444989B1 (en) 2008-04-18 2013-05-21 Boehringer Ingelheim Vetmedica Gmbh One dose vaccination against mycoplasma infections of pigs
US20100150959A1 (en) 2008-12-15 2010-06-17 Vectogen Pty Ltd. PCV 2-Based Methods and Compositions for the Treatment of Pigs
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
WO2011075379A1 (en) 2009-12-18 2011-06-23 Boehringer Ingelheim Vetmedica, Inc. Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
HUE047972T2 (hu) 2010-03-16 2020-05-28 Virginia Tech Intellectual Properties Inc Gyengített, élõ kiméra sertés cirkovírus vakcina
US9580474B2 (en) 2010-09-08 2017-02-28 The Johns Hopkins University Polyionic papilloma virus-like particle (VLP) vaccines
CN103122352B (zh) 2012-09-27 2015-02-11 华中农业大学 一种猪圆环病毒2型重组杆状病毒及制备方法和应用
US9624527B2 (en) 2013-03-01 2017-04-18 Boehringer Ingelheim Vetmedica, Inc. Quantification of vaccine compositions
CN105246505A (zh) 2013-04-30 2016-01-13 勃林格殷格翰动物保健公司 PCV2a亚型(PCV2a)的ORF2蛋白用于交叉保护中的用途
US20140348874A1 (en) 2013-05-22 2014-11-27 Boehringer Ingelheim Espana, S.A. Method for the reduction of pcv-2 in a herd of swine
HUE060972T2 (hu) 2013-08-23 2023-05-28 Boehringer Ingelheim Animal Health Usa Inc 2-es típusú sertés cirkovírus (PCV) alegység vakcina
ES2778425T3 (es) 2013-10-02 2020-08-10 Boehringer Ingelheim Animal Health Usa Inc Variante de la proteína ORF2 del PCV2 y partículas similares a virus compuestas por esta
CA2948071C (en) 2014-05-07 2022-08-30 Boehringer Ingelheim International Gmbh Container, nebulizer and use
US10555994B2 (en) 2015-03-30 2020-02-11 Boehringer Ingelheim Animal Health USA Inc. PCV2 ORF2 carrier platform

Also Published As

Publication number Publication date
DK3127551T3 (da) 2020-10-12
EP2371382B1 (en) 2016-03-02
US20160193320A1 (en) 2016-07-07
US9669087B2 (en) 2017-06-06
US20080279876A1 (en) 2008-11-13
US20080279889A1 (en) 2008-11-13
EP2374476A1 (en) 2011-10-12
DK2371383T3 (en) 2015-11-30
AR058871A1 (es) 2008-02-27
MX338626B (es) 2016-04-26
JP5739602B2 (ja) 2015-06-24
WO2007094893A2 (en) 2007-08-23
EP1976558A4 (en) 2009-04-29
ES3067052T3 (en) 2026-05-19
EP2371386A1 (en) 2011-10-05
ES2824113T3 (es) 2021-05-11
HUE026205T2 (en) 2016-05-30
US7838213B2 (en) 2010-11-23
US10568955B2 (en) 2020-02-25
CN101426522B (zh) 2014-11-12
US20080260779A1 (en) 2008-10-23
US20080181910A1 (en) 2008-07-31
BRPI0620823A2 (pt) 2011-11-22
EP2275130A3 (en) 2011-03-23
EP2374475A1 (en) 2011-10-12
WO2007094893A9 (en) 2008-12-31
EP2371385A1 (en) 2011-10-05
PL3127551T3 (pl) 2020-12-28
PT3766518T (pt) 2026-04-07
SG170792A1 (en) 2011-05-30
EP2371384A1 (en) 2011-10-05
US20080261887A1 (en) 2008-10-23
PT2371385E (pt) 2015-11-27
CN104383526B (zh) 2018-09-18
ES2572736T3 (es) 2016-06-02
CA2635430A1 (en) 2007-08-23
PL2371383T3 (pl) 2016-01-29
ES2553253T3 (es) 2015-12-07
BRPI0620823B1 (pt) 2017-02-21
DK1976558T3 (en) 2017-06-19
EP2275130A2 (en) 2011-01-19
US9011868B2 (en) 2015-04-21
US20080279875A1 (en) 2008-11-13
US9987349B2 (en) 2018-06-05
EP1976558A2 (en) 2008-10-08
MX343001B (es) 2016-10-21
PT2371383E (pt) 2015-11-24
EP3127551B1 (en) 2020-07-29
EP3766518A1 (en) 2021-01-20
DK3766518T3 (da) 2026-04-13
HUE051784T2 (hu) 2021-03-29
CN104474541A (zh) 2015-04-01
WO2007094893A3 (en) 2008-11-06
US20170049875A1 (en) 2017-02-23
US9610345B2 (en) 2017-04-04
TW200800256A (en) 2008-01-01
PL3766518T3 (pl) 2026-06-01
AU2006338182B2 (en) 2013-08-22
KR20140019479A (ko) 2014-02-14
MX356667B (es) 2018-06-08
CN101426522A (zh) 2009-05-06
EP1976558B1 (en) 2017-03-15
KR20080093112A (ko) 2008-10-20
EP2371383B1 (en) 2015-08-19
US20150190498A1 (en) 2015-07-09
AU2006338182A1 (en) 2007-08-23
ES2625903T3 (es) 2017-07-20
US20180236057A1 (en) 2018-08-23
US7838214B2 (en) 2010-11-23
PL2371385T3 (pl) 2016-02-29
EP2371385B1 (en) 2015-08-19
EP2371382A1 (en) 2011-10-05
CN109125721A (zh) 2019-01-04
ES2553254T3 (es) 2015-12-07
DK2371382T3 (en) 2016-06-13
EP3766518B1 (en) 2026-01-28
US20080267995A1 (en) 2008-10-30
CN104383526A (zh) 2015-03-04
HUE029552T2 (en) 2017-03-28
JP2013067655A (ja) 2013-04-18
FI3766518T3 (fi) 2026-04-09
DK2371385T3 (en) 2015-11-30
CN104474541B (zh) 2019-08-23
JP2009522310A (ja) 2009-06-11
US7829273B2 (en) 2010-11-09
US20110217327A1 (en) 2011-09-08
EP3127551A1 (en) 2017-02-08
EP2371383A1 (en) 2011-10-05
US7968285B2 (en) 2011-06-28
PT3127551T (pt) 2020-10-09
HUE025994T2 (en) 2016-05-30
MX2008008311A (es) 2009-03-04

Similar Documents

Publication Publication Date Title
PL2371383T3 (pl) Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
IL254498B (en) Peptidomimetic macrocyclic composition for use in the treatment of diseases
IL223141A0 (en) Immunogenic composition for use in vaccination against staphylococcei
IL227934A0 (en) Immunogenic preparation
GB0427145D0 (en) Compositions for use in surgery
ZA200903860B (en) Treatment of PRDC in pigs
IL195787A (en) Polyphenol-containing preparations for use in enhancing cognitive activity in healthy patients
PL2144593T3 (pl) Środki do czyszczenia skóry i rąk z hydrofilowymi emolientami
IL205246A0 (en) Methods and compositions for diagnostic use in cancer patients
GB0617191D0 (en) Improvements in pharmaceutical compositions
ZA200806268B (en) Compositions for vaginal use
ZA200807486B (en) Medicament formulations comprising fluoroquinolones
PL2839836T5 (pl) Probiotyki do zastosowania przy redukowaniu objawów choroby układu oddechowego
EP2039340A4 (en) COMPOSITION FOR CLEANING THE SKIN
PL2046268T3 (pl) Kompozycja do pielęgnacji jamy ustnej
AU2013213661B2 (en) Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs
IL195602A (en) The arginine-based composition for oral administration
GB0606416D0 (en) Immunogenic composition
EP2150243A4 (en) COMPOSITIONS AND METHODS FOR REINFORCED ACTIVE SUBSTANCE ABSORPTION
ZA200605597B (en) Compositions for use with skin
GB2437457B (en) Game machine and self-running body for use therein
GB0803201D0 (en) Two-part dressing suitable for use in surgery
ZA200805750B (en) Care composition
GB0620687D0 (en) Disposable in one "use for plumming"
GB0614962D0 (en) Complex for use in vaccines